Organon & Co. (NYSE:OGN) Given Consensus Rating of “Reduce” by Analysts

Shares of Organon & Co. (NYSE:OGN) have been assigned a consensus rating of “Reduce” from the seven ratings firms that are covering the firm, MarketBeat.com reports. Three research analysts have rated the stock with a sell recommendation and four have issued a hold recommendation on the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $11.40.

A number of analysts recently issued reports on the company. Piper Sandler raised Organon & Co. from an “underweight” rating to a “neutral” rating and raised their price objective for the stock from $5.00 to $14.00 in a research report on Tuesday, April 28th. BNP Paribas Exane reissued a “neutral” rating and set a $14.00 price objective (up from $12.00) on shares of Organon & Co. in a research report on Wednesday, April 29th. Barclays raised their price objective on Organon & Co. from $7.50 to $8.00 and gave the stock an “underweight” rating in a research report on Tuesday, February 24th. Zacks Research raised Organon & Co. from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 14th. Finally, Wall Street Zen downgraded Organon & Co. from a “buy” rating to a “hold” rating in a research report on Saturday, January 31st.

Insider Activity

In other Organon & Co. news, SVP Lynette Holzbaur acquired 26,448 shares of the business’s stock in a transaction that occurred on Wednesday, May 6th. The stock was purchased at an average cost of $13.35 per share, with a total value of $353,080.80. Following the transaction, the senior vice president owned 52,851 shares of the company’s stock, valued at $705,560.85. This trade represents a 100.17% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 1.62% of the company’s stock.

Hedge Funds Weigh In On Organon & Co.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Sector Gamma AS purchased a new position in Organon & Co. during the 3rd quarter valued at about $5,807,000. Gotham Asset Management LLC boosted its holdings in Organon & Co. by 37.2% during the 3rd quarter. Gotham Asset Management LLC now owns 3,713,204 shares of the company’s stock valued at $39,657,000 after acquiring an additional 1,007,691 shares during the period. Vanguard Group Inc. boosted its holdings in Organon & Co. by 11.3% during the 3rd quarter. Vanguard Group Inc. now owns 35,928,403 shares of the company’s stock valued at $383,715,000 after acquiring an additional 3,650,860 shares during the period. Y Intercept Hong Kong Ltd purchased a new position in Organon & Co. during the 3rd quarter valued at about $2,000,000. Finally, Poehling Capital Management INC. boosted its holdings in Organon & Co. by 57.7% during the 3rd quarter. Poehling Capital Management INC. now owns 317,748 shares of the company’s stock valued at $3,394,000 after acquiring an additional 116,289 shares during the period. 77.43% of the stock is currently owned by hedge funds and other institutional investors.

Organon & Co. Stock Up 0.3%

Shares of OGN opened at $13.40 on Friday. Organon & Co. has a 52-week low of $5.69 and a 52-week high of $13.44. The company has a market capitalization of $3.52 billion, a PE ratio of 14.40, a price-to-earnings-growth ratio of 1.24 and a beta of 1.57. The stock has a fifty day simple moving average of $8.74 and a two-hundred day simple moving average of $8.01. The company has a quick ratio of 1.42, a current ratio of 1.97 and a debt-to-equity ratio of 9.47.

Organon & Co. (NYSE:OGN) last issued its quarterly earnings data on Thursday, April 30th. The company reported $0.71 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.83 by ($0.12). The business had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.49 billion. Organon & Co. had a return on equity of 99.95% and a net margin of 3.99%.The firm’s revenue for the quarter was down 3.5% compared to the same quarter last year. During the same period in the previous year, the business posted $1.02 earnings per share. As a group, equities analysts forecast that Organon & Co. will post 3.23 EPS for the current year.

Organon & Co. Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 11th. Investors of record on Monday, May 11th will be given a dividend of $0.02 per share. This represents a $0.08 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Monday, May 11th. Organon & Co.’s dividend payout ratio (DPR) is presently 8.60%.

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.